UK to host "human challenge" trials for COVID-19 vaccines - FT
Adds detail on trial, comments from AstraZeneca, Sanofi, background
Sept 23 (Reuters) - Britain will host clinical trials where volunteers are deliberately infected with the new coronavirus to test the effectiveness of vaccine candidates, the Financial Times reported on Wednesday, citing people involved in the project.
The government-funded project is expected to begin in January at a quarantine facility in London, the report said, adding that about 2,000 participants had signed up through a U.S.-based advocacy group, 1Day Sooner. (https://on.ft.com/2G5o0jP)
Any trials conducted in the United Kingdom have to be approved by the Medicines and Healthcare products Regulatory Agency (MHRA), the healthcare regulator which looks into safety and protocol.
The MHRA, 1Day Sooner and its 18-year old lead organizer, Alastair Fraser-Urquhart, did not immediately respond to Reuters' requests for comment.
The industry has seen discussions in recent months about potentially having to inject healthy volunteers with the novel coronavirus if drugmakers struggled to find enough patients for final trials.
The FT report said that volunteers would first be inoculated with a vaccine and later receive a challenge dose of the coronavirus. It did not name the vaccines that would be assessed in the project.
British drugmaker AstraZeneca AZN.L, whose experimental COVID-19 vaccine being developed with the University of Oxford is leading the race, told Reuters that it was not involved in the programme.
French firm Sanofi SASY.PA also told Reuters it was not part of the initiative.
Imperial College, which is developing its own coronavirus vaccine and is the academic partner of the programme, did not immediately respond to a request for comment.
(Reporting by Manas Mishra and Pushkala Aripaka in Bengaluru, Kate Kelland and Alistair Smout in London, Matthias Blamont in Paris, and Ludwig Burger in Frankfurt; Editing by Shinjini Ganguli and Jan Harvey)
((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manasmishra24; within U.S. +1 646 223 8780, outside U.S. +91 806749 2709;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.